Is Alnylam Stock Poised For More Gains After A Stellar 50% Rise In A Month?

Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

About the Author

has written 23415 stories on this site.

Copyright © 2010 corporatecommunicationsnews101.com